Target Price | KRW312,120.00 |
Price | KRW301,500.00 |
Potential |
3.52%
register free of charge
|
Number of Estimates | 29 |
29 Analysts have issued a price target LG Chem 2026 .
The average LG Chem target price is KRW312,120.00.
This is
3.52%
register free of charge
KRW525,000.00
74.13%
register free of charge
KRW252,500.00
16.25%
register free of charge
|
|
A rating was issued by 33 analysts: 27 Analysts recommend LG Chem to buy, 6 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the LG Chem stock has an average upside potential 2026 of
3.52%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion KRW | 48,916.10 | 49,087.31 |
11.46% | 0.35% | |
EBITDA Margin | 3.51% | 15.51% |
39.73% | 342.48% | |
Net Margin | -1.41% | 1.30% |
158.33% | 192.05% |
31 Analysts have issued a sales forecast LG Chem 2025 . The average LG Chem sales estimate is
This results in the following potential growth metrics:
27 Analysts have issued an LG Chem EBITDA forecast 2025. The average LG Chem EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
28 LG Chem Analysts have issued a net profit forecast 2025. The average LG Chem net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share KRW | -8,825.97 | 8,129.10 |
151.64% | 192.10% | |
P/E | 37.64 | |
EV/Sales | 0.92 |
28 Analysts have issued a LG Chem forecast for earnings per share. The average LG Chem EPS is
This results in the following potential growth metrics and future valuations:
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.